The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.

Name: Αlpha¹ Rigor Record — The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.
Item: The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.
Rating: 59
Author: Αlpha¹

Bryant JA, Vulić M, Walsh EA, Allen EG Jr, Beauchemin NJ, Chafee ME, Diao L, Fenn K, Ford KA, Hasson BR, Litcofsky KD, Lombardo MJ, Martinez A, O'Brien EJ, Straub TJ, Sykes SM, Marshall LF, Winkler JA, McGovern BH, Ford CB, Wortman JR, Henn MR

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 5 high issues for “The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Mixed Methods

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingEthical approvals partially met−0.25★
ReportingStatistical analysis partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Problems surfaced5 types

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps3

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Data/code availability incompleteAssessed
Ethics/consent reporting incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted post hoc analysis of a randomized trial with strong reporting transparency, ethical approvals, and scientific premise. Its main methodological weaknesses are in statistical reporting (p-value thresholds instead of exact values, missing effect sizes with CIs) and data/code sharing (no public repository deposit or code). A minor ethics reporting gap (no explicit regulatory framework) and a few copyedit issues also reduce the overall robustness.

Evaluated based on the full published paper. The two independent reviewer runs largely agreed, with minor divergences on checklist-level ratings (e.g., randomization method, demographics, regulatory compliance, reagents catalog numbers, and accession numbers) that were resolved by weighing the evidence. The statistics component could not verify any recomputations due to threshold-only p-values; no errors were found but no tests were confirmed correct. The citation check found no retracted or unresolved references. The integrity check flagged a concern about retrospective registration of one trial (NCT02437487).

8 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions5 pass · 3 warn

The paper cites prior work on bile acid and short-chain fatty acid mechanisms of C. difficile inhibition, the phase 1b/phase 2 results, and the hypothesis of suboptimal dosing. The rationale linking prior discordant outcomes to dosing is clearly stated, and the objectives (pharmacokinetic/engraftment comparison and mechanistic microbiome analysis) follow logically. Limitations of prior work (discordant phase 1b vs phase 2 results) are explicitly addressed as the motivation for the higher phase 3 dose.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The scientific foundation is well established with extensive prior literature, a clear rationale for the dose hypothesis, and acknowledgement of prior discordant trial results.

Evidence

direct quote[Main, paragraph 1]

“These discordant outcomes were hypothesized to be due to suboptimal dosing.”